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Objectives. We sought to determine the in-hospital clinical out-
come and angiographic results of patients prospectively entered into
the National Heart, Lung, and Blood Institute/New Approaches to
Coronary Intervention (NHLBI/NACI) Registry who received
Gianturco-Roubin stents as an unplanned new device.
Background. Between August 1990 and March 1994, nine
centers implanted Gianturco-Roubin flex stents as an unplanned
new device in the initial treatment of 350 patients (389 lesions)
who were prospectively enrolled in the NHLBI/NACI Registry.
Methods. Patients undergoing implantation of the Gianturco-
Roubin flex stent were prospectively entered into the Gianturco-
Roubin stent portion of the NHLBI/NACI Registry. Only subjects
receiving the Gianturco-Roubin stent as a new device in an
unplanned fashion are included.
Results. The mean age of the patient group was 61.8 years, and
the majority of the patients were men. A history of percutaneous
transluminal coronary angioplasty (PTCA) was present in 35.4%
of the group, and 16.9% had previous coronary artery bypass graft
surgery. Unstable angina was present in 67.7%. Double- or
triple-vessel coronary artery disease was present in 55.4%, and the
average ejection fraction was 58%. The presence of thrombus was
noted in 7.3%, and 7.2% had moderate to severe tortuosity of the
lesion. The angiographic success rate was 92%. Individual clinical
sites reported that 66.3% of the stents were placed after subopti-
mal PTCA, 20.3% for abrupt closure and 13.4% for some other
technical PTCA failure. Major in-hospital events occurred in 9.7%
of patients, including death in 1.7%, Q wave myocardial infarction
in 3.1% and emergency bypass surgery in 6%. Abrupt closure of a
stented segment occurred in 3.1% of patients at a mean of 3.9
days. Cerebrovascular accident occurred in 0.3%, and transfusion
was required in 10.6%. Vascular events with surgical repair
occurred in 8.6% of patients.
Conclusions. Despite these complications, the use of this device
for the treatment of a failed or suboptimal PTCA result remains
promising given the adverse outcome of abrupt closure with
conventional (nonstent) treatment.
(J Am Coll Cardiol 1997;29:934–40)
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Since the original description by Gruentzig et al. (1) of
percutaneous transluminal coronary angioplasty (PTCA), a
plethora of new coronary devices have been introduced to
offset the drawbacks of PTCA. However, indications for use,
risks and long-term efficacy of individual devices in the treat-
ment of coronary artery disease remain to be completely
defined. With this in mind, on November 1, 1990, the National
Heart, Lung, and Blood Institute (NHLBI) implemented the
New Approaches to Coronary Intervention (NACI) Registry
(2). This manuscript describes the initial experience and
in-hospital outcome in patients receiving the Gianturco-
Roubin flex stent (Cook Inc.) who participated in the NACI
Registry.
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Gianturco-Roubin stent (GRS) placement routinely follows
either rescue for failed PTCA (manifested by early closure) or
suboptimal PTCA (as determined by the individual practitio-
ner, but typically based on some notion of “threatened clo-
sure”). This report describes the use of GRS in the patients
enrolled in NACI and compares patients and lesions in which
the stent was used as a bail-out for abrupt closure or other
immediate complications after PTCA versus those in which the
mode for use was “corrective” after a suboptimal PTCA result.
Methods
Data collection. Forty-one sites in North America partici-
pated in the Registry. Consecutive patients undergoing percu-
taneous intervention at a Registry site were included. All
patients gave written informed consent to participate in the
NACI Registry, and the individual sites had the approval of
their Institutional Review Board before establishment of the
Registry. In-hospital data including demographics, clinical
history, operator-assessed angiographic or fluoroscopic vari-
ables, the nature of the procedure and outcomes were col-
lected from each patient. Standard forms (2) were used and
sent to the coordinating center at the University of Pittsburgh,
where they were checked for validity and consistency. Resolu-
tion of any discrepancies was coordinated between the data
collection center and the individual site, and all data were then
entered into a data base. The angiographic recording of each
procedure, whether successful or unsuccessful, was sent to a
central angiographic core laboratory (Washington Heart Cen-
ter). The films were then independently assessed using com-
puterized edge detection algorithms. In addition, other lesion-
specific morphologic characteristics were determined.
Subjects. From the Registry data base, we selected records
from subjects who received a GRS. To analyze the effect of
GRS without confounding by the concurrent use of other
devices, we excluded subjects who also received treatment with
other new devices. The adjunctive use of other new devices
after GRS occurred rarely in the Registry. Only two patients
who received Wiktor stents after GRS were excluded from the
analysis. Because this stent is used primarily as an unplanned
device and only 61 patients were registered as planned GRS
recipients, we have only included subjects who received a GRS
as an unplanned device during the procedure. However, we
report on all attempts to use the GRS for this indication. A
patient was entered into the Registry when the stent package
was opened. Between August 1990 and August 1994, baseline
NACI Registry data from 4,421 patients were verified and
entered into the data base. Of these, 350 patients (389 lesions)
at the nine GRS sites met the criteria. According to the site
reports, 66.7% of the stent placements were for the treatment
of suboptimal results with previous PTCA. The bail-out indi-
cation accounted for 33.3% of GRS use (20.1% for abrupt
closure and 13.2% for some other PTCA technical failure).
Sites were not held to a specific angiographic definition when
reporting the mode for stent use.
End points. The procedure was considered to be successful
if reduction of the target lesion (without emergency bypass
surgery, myocardial infarction or death) was by at least 20%
with ,50% final diameter stenosis by core angiographic labo-
ratory assessment. The major clinical end point was in-hospital
death, myocardial infarction and bypass surgery. We moni-
tored other complications such as abrupt stent closure (i.e., any
in-hospital repeat revascularization of the treated vessel),
coronary dissection, perforation and major bleeding.
Analysis. We categorized lesions into two groups: those in
which GRS was a “bailout” device (i.e., site reported place-
ment owing to abrupt closure or some other previous PTCA
failure) versus “corrective” device (i.e., site reported mode for
use was “suboptimal PTCA”). Six patients who had lesions
treated for both reasons were placed in the bailout category.
We employed logistic regression analysis to identify any vari-
ables likely to discriminate between the two groups. Any
trendworthy variables (p , 0.10) were then entered simulta-
neously in a multiple logistic regression model, and a backward
selection procedure was used to eliminate all but those factors
which independently discriminated between the two groups
with statistical significance (p , 0.05). We then employed
multiple logistic regression analysis to identify which factors
(including bailout vs. “corrective” use) were independently
associated with major in-hospital complications. Angiographic
variables are only reported from those patients with core
laboratory data.
Results
Patient-specific characteristics. Both the bailout group
and “corrective” group had similar clinical history profiles
(Table 1). Patients were predominately (60.9%) men with a
mean age of 61.8 years. Of the patients 35.4% had previous
PTCA at a median time of 4.6 months earlier. A history of
previous myocardial infarction was present in 52%, 30.3%
within 6 weeks of the procedure. Angina was the primary
reason for revascularization in 85.2% of the subjects, and in
67.7% it was unstable. Only 44% of the patients had single-
vessel disease; 24.1% had three-vessel disease. The average
ejection fraction was 58%. The average length of hospital stay
was 9.26 days. No patient-specific characteristics showed any
statistically significant difference between the groups.
Lesion-specific characteristics. Of the 389 lesions in this
report, 361 (92.8%) underwent core laboratory assessment
(Table 2). The site reported readings on the subset closely
Abbreviations and Acronyms
E-CABG 5 emergency coronary artery bypass graft surgery
GRS 5 Gianturco-Roubin stent
NACI 5 New Approaches to Coronary Intervention
NHLBI 5 National Heart, Lung, and Blood Institute
PTCA 5 percutaneous transluminal coronary angioplasty
QMI 5 Q wave myocardial infarction
TIMI 5 Thrombolysis in Myocardial Infarction
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parallels those of the full study, indicating that there was no
appreciable selection bias with respect to the films being sent.
Of stented vessels 42.6% were in the right coronary artery,
32.6% in the left anterior descending coronary artery, 18.1% in
the left circumflex artery, 3.9% in a bypass graft and 0.8% in
the protected left main coronary artery. Angiographic evidence
of thrombus was present in 7.3%, and 21.9% had angiographic
evidence of calcium. Of the lesions 23.4% represented reste-
noses. The mean reference vessel diameter was 3.04 mm, with
a minimal lumen diameter of 0.80 mm (73.5% stenosis) before
the procedure. The lesions averaged 12.80 mm in length, and
28.8% were $15 mm in length. The rescue group was distin-
guished by more total occlusions (17.1% vs. 3.2%, p , 0.01),
worse Thrombolysis in Myocardial Infarction (TIMI) flow
grade (28.8% vs. 7.5%, 0 or 1, p , 0.01) and more severe
dissection (17.0% vs. 5.1%, grade F, p , 0.01) before stenting.
There was no significant difference between the groups in any
procedural angiographic characteristics, and stenting resulted
in angiographic success in 92% of the treated segments.
Stent size and length. The most commonly used stent size
was 3 mm, and the majority of patients (76%) had a $3-mm
stent placed. The use of the 2-mm diameter stent is decidedly
rare (0.3%) in the Registry, probably representing concerns
over abrupt closure and the risk/benefit ratio with regard to the
requirements for anticoagulation after stent placement. Al-
though stents both 12 and 20 mm in length were available
during Registry enrollment, the majority of patients had the
20-mm length stent placed (61.6% had 20 mm and 38.4% had
12 mm).
The most frequent device complication was failure to cross
the lesion with the device in 3.9%, which was equally common
in both groups (3.8% in bail-out group vs. 3.9% in corrective
group). The stent was withdrawn in 3.3% of the lesions
attempted.
Major in-hospital events. Table 3 shows that death, Q
wave myocardial infarction (QMI) and emergency coronary
artery bypass graft surgery (E-CABG) were twice as prevalent
in the bailout group. Except for QMI, the difference in rates
was statistically significant (p , 0.01). The overall in-hospital
mortality rate was 1.7%, with a QMI rate of 3.1% and an
E-CABG rate of 6%. Death, QMI or E-CABG, or a combi-
nation of these, occurred in 9.7% overall. Abrupt vessel closure
occurred within the first 24 h after the procedure in 0.6%, with
a cumulative in-hospital occurrence rate of 3.1% (mean 3.9
days, range 0 to 5 after stenting). Hemorrhage requiring
transfusion occurred in 10.6%, and vascular events requiring
surgical treatment occurred in 8.6%. There was no difference
between the bailout and corrective groups. Clinical evidence of
cerebrovascular accident in the hospital occurred in 0.3%.
Table 4 shows the logistic regression estimates of significant
patient and lesion characteristic effects on major in-hospital
complications (death, E-CABG or QMI). Because the bailout
group clearly had a distinctly elevated rate, that factor was
forced into every model. Adjusting only for bailout use, a
number of factors were significant, especially recent myocar-
dial infarction, multivessel disease, severe dissections and poor
TIMI flow before stenting and smaller lumen diameter after
the procedure. A final multiple logistic regression model is
presented in Figure 1. This shows that major complications
were more common in patients with a recent myocardial
infarction, multivessel disease, tortuous lesions and at least one
attempted lesion with .40% postresidual stenosis. The re-
duced sample size (290 patients with complete data) and the
low number of events (24 events) limit the power to rule out
other potential predictors of complications. Therefore, caution
should be used in the interpretation of these results.
After a similar analysis of factors associated with repeat
revascularization (CABG or target PTCA) within 10 days after
the stent attempt, a number of significant clinical and angio-
graphic factors were identified. Patients with high residual
stenoses or residual thrombi are more likely to need reinter-
vention. As with in-hospital complications, this analysis is
limited by the low event rate and the number of cases with
complete data (27 events in 253 patients).
Discussion
We report the initial experience and in-hospital outcome in
a diverse group of patients receiving the GRS for bailout or
corrective use at nine different institutions involved in the
NHLBI/NACI Registry. This Registry represents a unique
data set in that it was prospectively collected, monitored for
accuracy by the data coordinating center and had core labora-
Table 1. Patient Characteristics
Mode for Stent Use
All Subjects
(n 5 350)
Rescue
(n 5 118)
Corrective
(n 5 232)
Mean age (yr) 61.8 60.6 62.4
Male 60.9 62.7 59.9
Prior PTCA 35.4 34.7 35.8
Prior CABG 16.9 18.6 15.9
History of
MI 52.0 55.1 50.4
CHF 8.3 8.0 8.4
Diabetes 16.4 17.9 15.6
Hypertension 51.1 53.0 50.2
CAD 39.4 42.6 37.6
Hypercholesterolemia 49.3 45.7 51.3
Never smoked 38.9 34.7 40.9
Unstable angina 67.7 66.1 68.5
MI within 6 wk 30.3 30.5 30.2
No. diseased vessels
1 44.0 45.3 43.3
2 31.3 34.2 29.9
3 24.1 20.5 26.0
Mean LVEF (%) 58.0 56.1 59.1
No. of patients 193 68 125
Data presented are percent of patients, unless otherwise indicated.
CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery
disease; CHF 5 congestive heart failure; LVEF 5 left ventricular ejection
fraction; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal
coronary angioplasty.
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tory quantification and verification of angiographic results. It is
the only report of the use of this device with independent
angiographic core laboratory verification of the angiographic
results. It reports the results of all patients undergoing GRS
implantation in an unplanned fashion, including those with
unsuccessful GRS deployment. This report should serve as a
new benchmark to compare similar devices (i.e., other stents)
or techniques (e.g., prolonged balloon inflation) for the indi-
cations presented.
Coronary angioplasty and abrupt closure. Although there
have been substantial improvements in PTCA balloon, guiding
catheter and guide wire technology, abrupt closure continues
to occur in ;2% to 10% (3,4), or higher (5), of patients
undergoing interventional procedures. The incidence of abrupt
closure appears to be a constant potential complication with
angioplasty, as a comparison of the NHLBI/PTCA Registry
(6,7) results shows that despite a more complex patient subset
Table 3. Rates of Major In-Hospital Complications
All
Subjects
(n 5 350)
Rescue
(n 5 118)
Corrective
(n 5 232)
Death 1.7% 4.2% 0.4%*
Emergency CABG 6.0% 11.0% 3.4%†
Any CABG 8.6% 15.3% 5.2%†
Any MI 12.0% 17.8% 9.1%*
Q wave MI 3.1% 3.4% 3.0%
Death/CABG/Q
wave MI
9.7% 16.1% 6.5%†
Any complication 19.1% 30.5% 13.4%†
(death/CABG/MI)
Procedural success 85.1% 80.5% 87.1%
No. of patients 288 87 201
*p , 0.05. †p , 0.01. Abbreviations as in Table 1.
Table 2. Lesion Characteristics
All Subjects Rescue Corrective
No. of leions 389 131 258
No. with core laboratory reading 369 122 247
Restenotic lesion 23.4% 16.2% 26.7%*
Location
RCA 42.6% 47.0% 40.5%
LAD 32.6% 32.5% 32.6%
LCx 18.1% 13.7% 20.2%
CABG 3.9% 2.6% 4.5%
LMCA 0.8% 0.9% 0.8%
Thrombus 7.3% 10.2% 6.0%
Tortuosity
Severe 1.7% 3.7% 0.9%
Moderate 5.5% 7.4% 4.7%
None 92.7% 88.9% 94.5%
Eccentricity 37.0% 37.0% 37.0%
Calcium 21.9% 11.1% 21.3%
Ulcerated 12.3% 12.5% 12.9%
Mean lesion length (mm) 12.80 11.84 13.21
Ref vessel size (mm) 3.04 3.08 3.03
Before PTCA
MLD (mm) 0.80 0.83 0.79
% stenosis 73.5% 72.1% 74.1%
Total occlusion 19.3% 21.8% 17.0%
TIMI flow grade
0 16.3% 18.5% 15.3%
1 5.5% 4.6% 6.0%
2 8.2% 7.4% 8.5%
3 70.0% 69.4% 70.2%
ACC/AHA dissection grade
A 0.3% 0.0% 0.4%
B 0.9% 0.9% 0.9%
C 2.3% 2.8% 2.1%
D 5.0% 5.6% 4.7%
E 1.5% 1.9% 1.3%
F 1.7% 3.7% 0.9%
Before stent
MLD (mm) 1.47 1.12 1.50
% stenosis 51.23% 63.3% 49.5%
Total occlusion 7.7% 17.1% 3.2%†
TIMI flow grade †
0 5.8% 12.8% 2.8%
1 8.1% 16.0% 4.7%
2 7.8% 7.4% 7.9%
3 78.3% 63.8% 84.7%
ACC/AHA dissection grade †
A 2.9% 2.1% 3.3%
B 13.6% 4.3% 17.7%
C 23.6% 18.1% 26.0%
D 25.2% 14.9% 29.8%
E 5.8% 7.4% 5.1%
F 8.7% 17.0% 5.1%
After procedure
MLD (mm) 2.38 2.44 2.35
% stenosis 22.40% 22.67% 22.28%
Total occlusion 0.0% 0.0% 0.0%
TIMI flow grade
0 0.0% 0.0% 0.0%
1 0.9% 2.0% 0.4%
2 0.9% 0.0% 1.3%
3 98.2% 98.0% 98.2%
Table 2 (continued).
All Subjects Rescue Corrective
ACC/AHA dissection grade
A 8.3% 7.1% 8.8%
B 12.0% 10.1% 12.8%
C 11.1% 10.1% 11.5%
D 8.3% 12.1% 6.6%
E 0.9% 1.0% 0.9%
F 0.3% 0.0% 0.4%
Angiographic lesion success
Change .20% and residual stenosis
,50%
92.0% 90.8% 92.4%
TIMI flow grade 3 and residual stenosis
,50%
93.5% 93.9% 93.3%
Residual stenosis ,50% 94.4% 94.9% 94.2%
*p , 0.05. †p , 0.01. ACC/AHA 5 American College of Cardiology/
American Heart Association; CABG 5 coronary artery bypass graft surgery;
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary
artery; LMCA 5 left main coronary artery; MLD 5 minimal lumen diameter;
PTCA 5 percutaneous transluminal coronary angioplasty; RCA 5 right coro-
nary artery; Ref 5 reference; TIMI 5 Thrombolysis in Myocardial Infarction
trial.
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in the 1985 to 1986 registry, the incidence of abrupt closure was
similar to the earlier registry. Newer devices including rota-
tional and directional atherectomy (8,9), laser angioplasty (10)
and perfusion balloon technology (11) have not yielded con-
sistent results in reducing the rate of abrupt closure or its
treatment.
The GRS appears to be effective in stabilizing the lumen of
a coronary vessel after complicated angioplasty (12). It also
appears to decrease the rate of subsequent QMI, emergency or
in-hospital CABG and perhaps mortality compared with his-
toric controls. Because the Registry is not a randomized trial to
compare the efficacy of the GRS to that of conventional
angioplasty, the results must therefore be compared to other
retrospective and prospective nonrandomized PTCA trials,
which can serve as historic controls.
Effect of stenting on abrupt or threatened closure. In the
initial experience with balloon angioplasty, failure of the tech-
nique was associated with the need for E-CABG in the majority
of patients. Emergency CABG is associated with increased mor-
bidity and mortality after failed angioplasty. The incidence of
QMI ranges from 11% to 61% in the published data (13,14). It
also appears that the incidence of death after E-CABG for failed
angioplasty is also increased, ranging from no deaths reported in
some series to 12% or higher (15–17). In addition, as reported in
the 1985 to 1986 NHLBI/PTCA Registry (7), the occurrence of
abrupt vessel closure complicating PTCA was not only associated
with a higher in-hospital mortality and morbidity, but also with a
higher incidence of myocardial infarction and death in the 18
months after the procedure. Clearly, abrupt closure after PTCA is
not a benign event in the hospital or in follow up.
The concept of threatened closure after PTCA is somewhat
more problematic because there is no unifying definition of the
event. Attempts have been made to define the process of
threatened closure, with Roubin et al. (18) defining threatened
closure as having one or more of the following: $50% residual
stenosis after PTCA, dissection $15 mm in length, TIMI flow
grade 2 (19) after PTCA and ongoing myocardial ischemia
manifested by continued chest pain, persistent electrocardio-
graphic changes consistent with ischemia, cardiac arrhythmias
or hemodynamic instability. In a more recent report Ferguson
et al. (20) attempted to risk-stratify patients with suboptimal
angioplasty results into subgroups that are likely to have a poor
clinical outcome. Despite attempts at defining threatened
closure more clearly, it nonetheless continues to be somewhat
imprecise and in all likelihood will never be defined to the
degree of abrupt closure. However, a suboptimal angioplasty
result or threatened closure is clearly associated with a poorer
outcome in the hospital and in follow up (21,22). In this report,
a severe dissection after PTCA, independent of total occlusion
and postprocedural stenosis, shows a trend toward predicting
major in-hospital complications.
In the treatment of abrupt or threatened closure, which
represented most of the patients in this report, the incidence of
death was 1.7%, QMI 3.1% and E-CABG 6%. These data
compare favorably with the previously published historic data
as discussed. The use of historic controls requires us to assume
that bail-out cases from earlier years would be comparable to
the cases selected for bail-out stenting in more recent series,
whereas nonrandom effects such as evolving patient selection
Figure 1. Multiple logistic regression model of site and core laboratory
factors associated with major in-hospital complications (249 lesions,
290 patients, 24 events). MI 5 myocardial infarction.
Table 4. Logistic Regression Analysis of Core Laboratory Factors
Associated With Major Complications (death, Q wave myocardial
infarction or emergency coronary artery bypass graft surgery):
Odds Ratio (95% confidence interval)
Adjusted Only
for Rescue
(p , 0.10)
Adjusted for All Factors
(p , 0.05) and Bailout
(n 5 290, 24 events)
Bailout use 2.78 (1.36–5.69) 2.34 (0.89–6.12)
MI in past 6 wk 2.99 (1.44–6.20) 4.77 (1.83–12.47)
Multivessel disease 2.50 (1.12–5.57) 4.03 (1.27–12.73)
Before procedure
LAD lesions 0.42 (0.18–1.01)
LCx lesions 0.30 (0.08–1.04)
CABG lesions 0.48 (0.06–3.99)
LMCA lesions 2.10 (0.17–25.65)
Class B2 or C lesions 7.64 (1.78–32.83)
Tortuous lesions 3.27 (1.15–9.30) 3.33 (0.83–13.43)
Before stent
Abrupt closure 3.08 (1.25–7.73)
Grade D dissections 0.67 (0.21–2.13)
Grade E dissections 1.31 (0.27–6.39)
Grade F dissections 3.43 (1.20–9.83)
TIMI flow grade 0 lesions 2.00 (0.50–8.06)
TIMI flow grade 1 lesions 3.56 (1.18–0.48)
TIMI flow grade 2 lesions 1.81 (0.48–6.84)
After procedure
MLD ,2 mm 2.85 (1.19–6.82)
20–40% diameter stenoses 1.34 (0.47–3.83) 1.04 (0.34–3.18)
40–100% diameter stenoses 7.80 (2.61–23.36) 6.27 (1.94–20.28)
TIMI flow grade 0 lesions NA
TIMI flow grade 1 lesions 4.72 (0.39–56.47)
TIMI flow grade 2 lesions 8.00 (0.68–94.59)
Lesions with thrombus 2.80 (0.84–9.35)
Because patients may have multiple lesions, categories of angiographic risk
factors are not mutually exclusive. Patients with missing core laboratory readings
were excluded. NA 5 not applicable; other abbreviations as in Tables 1 and 2.
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remain uncontrolled. In contrast, the NHLBI/PTCA and
NHLBI/NACI registries provide us with heterogeneous pools
of cases that are uniformly collected from multiple centers, and
probably offer the closest approximation to a “real world
comparison.”
There are several modes of GRS use observed by NACI that
are beyond the scope of this report. A cohort of 77 patients who
had GRS implantation in conjunction with another new device
was excluded from this report. To our knowledge, no data have
been published that address the performance of GRS as a
bail-out for atherectomy, other stents or lasers. A detailed report
comparing these circumstances with the unplanned use after
PTCA described in this report will greatly enhance our under-
standing of unplanned stenting.
Complications of stenting. This stent, as well as others
(23,24), requires meticulous attention to detail regarding im-
plantation, anticoagulation and nursing care. As demonstrated
by George et al. (25), in their review of the Cook registry data,
there is a definite learning curve regarding the need for blood
transfusion and vascular surgical repair of groin complications.
This is probably due to improved operator and ancillary
personnel experience in the management of these patients
after stent placement. Overanticoagulation definitely impacts
both morbidity and mortality after stent placement.
The need for anticoagulation is directed toward the concern
over abrupt closure after stent placement. Liu et al. (26)
reported by multivariate analysis that three factors increase the
likelihood of abrupt stent thrombosis with this device: a stent
,3 mm in diameter, a residual filling defect or a residual
dissection after stent deployment. The incidence of stent
thrombosis in a group of patients having the device placed for
abrupt or threatened closure was 1% in patients who had none
of the above risk factors, 8% in those with one risk factor and
28% in those with two or more risk factors. In the NACI
Registry, 24% of the stents placed were ,3 mm in size, 32.6%
of the stents placed had some dissection (grades B to F)
present after stenting and 6.2% had evidence of residual
thrombus. In addition, the minimal lumen diameter of
2.38 mm after stent placement suggests incomplete stent
expansion. The routine use of high pressure balloon inflation
after stent placement to ensure complete stent expansion was
not done in the Registry. A recent report (27) suggests that this
may impact both the initial angiographic result, abrupt stent
closure and restenosis rates in follow-up. The incidence of
abrupt closure after placement of the GRS in the NACI
Registry is similar to that seen in previous reports with this
device using a similar implantation technique (25). A recent
report from Europe with this stent (28) and another report
(29) suggest that for de novo and bail-out indications in large
vessels, anticoagulation can be markedly reduced and in some
cases eliminated entirely. Appropriate patient selection for
intracoronary stenting will continue to impact the abrupt and
long-term complications of the procedure.
Conclusions. Despite the limitations of this device, it ap-
pears to have great promise in the treatment of abrupt or
threatened closure after PTCA. It will no doubt have a
profound impact on the selection of patients undergoing
PTCA, potentially allowing for more complex clinical and
lesion subsets, thus expanding the horizons of patients under-
going PTCA. It will likewise have an impact on health care
expenditure by allowing patients with a “bail-out” procedure to
avoid the morbidity, mortality and increased cost of undergo-
ing E-CABG after failed angioplasty (30). It is premature,
however, to suggest that surgical standby for PTCA and the
performance of PTCA in hospitals without on-site access to
cardiovascular surgery be endorsed.
Caution should be exercised in appropriate patient selec-
tion, and meticulous attention to poststent management.
Hopefully, with new developments in stent technology, as have
occurred in balloon angioplasty, devices will become more
easily placed and require less aggressive or no anticoagulation
after placement. These potential improvements will greatly
impact the morbidity and mortality connected with stenting for
abrupt or threatened closure after PTCA.
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